APA (7th ed.) Citation

Rapoport, B., Chua, D., Poma, A., Arora, S., Wang, Y., Fein, L., & Fein, L. E. (2015). Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Supportive Care in Cancer, 23(11), 3281. https://doi.org/10.1007/s00520-015-2738-1

Chicago Style (17th ed.) Citation

Rapoport, Bernardo, Daniel Chua, Allen Poma, Sujata Arora, Yan Wang, Luis Fein, and Luis Enrique Fein. "Study of Rolapitant, a Novel, Long-acting, NK-1 Receptor Antagonist, for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) Due to Highly Emetogenic Chemotherapy (HEC)." Supportive Care in Cancer 23, no. 11 (2015): 3281. https://doi.org/10.1007/s00520-015-2738-1.

MLA (9th ed.) Citation

Rapoport, Bernardo, et al. "Study of Rolapitant, a Novel, Long-acting, NK-1 Receptor Antagonist, for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) Due to Highly Emetogenic Chemotherapy (HEC)." Supportive Care in Cancer, vol. 23, no. 11, 2015, p. 3281, https://doi.org/10.1007/s00520-015-2738-1.